⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ADAG News
Adagene Inc. American Depositary Shares
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
globenewswire.com
ADAG
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
globenewswire.com
ADAG
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
globenewswire.com
ADAG
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
globenewswire.com
ADAG
INCY
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
globenewswire.com
ADAG
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
ADAG
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
globenewswire.com
ADAG
Adagene to Participate in Two Upcoming Investor Conferences
globenewswire.com
ADAG
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
prnewswire.com
PFE
ABBV
TSE
GSK
ADAG
IMUX